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Abstract
Background: Previously we demonstrated that DNA vaccination of nonhuman primates (NHP) with a small subset
of vaccinia virus (VACV) immunogens (L1, A27, A33, B5) protects against lethal monkeypox virus challenge. The L1
and A27 components of this vaccine target the mature virion (MV) whereas A33 and B5 target the enveloped
virion (EV).
Results: Here, we demonstrated that the antibodies produced in vaccinated NHPs were sufficient to confer
protection in a murine model of lethal Orthopoxvirus infection. We further explored the concept of using DNA
vaccine technology to produce immunogen-specific polyclonal antibodies that could then be combined into
cocktails as potential immunoprophylactic/therapeutics. Specifically, we used DNA vaccines delivered by muscle
electroporation to produce polyclonal antibodies against the L1, A27, A33, and B5 in New Zealand white rabbits.
The polyclonal antibodies neutralized both MV and EV in cell culture. The ability of antibody cocktails consisting of
anti-MV, anti-EV, or a combination of anti-MV/EV to protect BALB/c mice was evaluated as was the efficacy of the
anti-MV/EV mixture in a mouse model of progressive vaccinia. In addition to evaluating weight loss and lethality,
bioimaging technology was used to characterize the spread of the VACV infections in mice. We found that the
anti-EV cocktail, but not the anti-MV cocktail, limited virus spread and lethality.
Conclusions: A combination of anti-MV/EV antibodies was significantly more protective than anti-EV antibodies
alone. These data suggest that DNA vaccine technology could be used to produce a polyclonal antibody cocktail
as a possible product to replace vaccinia immune globulin.
Keywords: Smallpox, vaccinia immunoglobulin, monoclonal antibody, passive protection, DNA vaccine, polyclonal
antibody, bioluminescence
Background
Naturally occurring smallpox has been eradicated. How-
ever, the possibility that smallpox, caused by variola
virus (VARV), or a genetically engineered Orthopoxvirus,
might be reintroduced through a nefarious act remains a
low-probability, but high-impact threat. Additionally,
monkeypox virus (MPXV) is an emerging virus that
causes endemic disease in central Africa and cowpox
has caused sporadic serious cases of disease in Europe.
These zoonotic viruses have the potential to spread and
cause morbidity and mortality in animals and humans
[1-4]. Examples of such unexpected long-range spread
of these diseases include the monkeypox outbreak in
midwestern United States [5] and the recent cowpox
outbreaks in Germany [6]. Currently licensed medical
countermeasures to prevent Orthopoxvirus disease
include a live-virus vaccine [7], and vaccinia immune
globulin intravenous (VIGIV) to treat adverse events
associated with that vaccine [8].
The licensed smallpox vaccine (ACAM2000) is com-
prised of live-vaccinia virus (VACV) delivered to the
skin using a bifurcated needle [7,9]. The health risks
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[10,11] necessitate that supplies of VIGIV be available in
sufficient quantities to treat certain adverse events asso-
ciated with the vaccine including eczema vaccinatum,
progressive vaccinia, severe generalized vaccinia, VACV
infections in individuals who have skin conditions, and
other aberrant VACV infections [12]. VIGIV is a US-
licensed drug manufactured by the fractionation of
hyperimmune plasma derived from persons vaccinated
with the live-VACV vaccine [13]. While vaccinia
immune globulins have been used in various forms for
decades [14-17], efficacy has not been demonstrated in
placebo-controlled clinical trials due both to the rare
nature of vaccinia-related adverse events and ethical
concerns regarding withholding of potentially effective
treatments [13]. As is the case with nearly all polyclonal
products, the relative protective contribution of the indi-
vidual antibodies that compose VIGIV are not well
understood. Because the hyperimmune plasma is
obtained from persons vaccinated with ACAM2000, it
contains not only protective antibodies, but also VACV-
specific antibodies that do not contribute to protective
immunity. It may be possible to replace this immu-
notherapeutic with a more defined product comprised
of a cocktail of polyclonal or monoclonal antibodies tar-
geting key protective epitopes in VACV.
Only a small subset of the ~200 open reading frames
in the Orthopoxvirus genome encode proteins that have
been implicated in protective immunity. Most of these
proteins are found on the surfaces of the two infectious
forms of orthopoxviruses: the mature virion (MV) and
the extracellular enveloped virion (EV). Targets include
the MV proteins encoded by the L1R, A27L, D8L, H3L
open reading frames; and the EV proteins encoded by
A33R and B5R [18-39]. Studies involving active vaccina-
tion with protein- or gene-based subunit vaccines, as
well as passive transfer studies using monoclonal antibo-
dies, have found that combinations of MV and EV tar-
gets afford improved protection over MV or EV alone
[24,30,31].
Based on the safety profile of Dryvax, ACAM2000,
and other live-vaccinia-based vaccines [7,10,11], a safer
(poorly replicating) smallpox vaccine would be ideal,
especially for at-risk populations. One such vaccinia
strain, modified vaccinia Ankara (MVA) has been the
focus of extensive research to determine if it is an
acceptable alternative to existing vaccinia strains. MVA
and its derivative strains are highly attenuated, and
undergo limited replication in primate cells [40]. While
the MVA-based vaccines are immunogenic and have a
favorable safety profile, higher doses of vaccine and mul-
tiple administrations of vaccine are required to achieve
adequate titers. Moreover, the duration of immunity
(both humoral and cellular) remains a concern with the
MVA-based vaccine candidates. An alternative approach
for the development of safer yet efficacious vaccines is
to avoid the use of live-virus-based vaccines entirely and
instead identify specific subunits or epitopes from
Orthopoxvirus species that confer protection and vacci-
nate with those subunits. Protein- and gene-based subu-
nit vaccines against orthopoxviruses have been
investigated by a number of groups [18-39,41-44]; for
review see [45]. Our laboratory has focused on gene-
based vaccines involving a combination of two MV and
two EV targets. The four-target combination (L1R,
A27L, A33R, and B5R) has been termed 4pox for simpli-
city. This vaccine delivered by various technologies has
protected mice, rabbits, and nonhuman primates (NHP)
against VACV [28,31,33], rabbitpox virus (Hooper, J.W.,
et al manuscript forthcoming), and monkeypox virus
[32,34] and Golden, J.W., et al manuscript forthcoming).
Here, we investigated the protective efficacy of antibo-
dies elicited by the 4pox DNA vaccine. We found that
serum from immune NHP or rabbits could provide
complete protection from lethality in VACV intranasal
murine challenge models, as well as partial protection in
a mouse model of progressive vaccinia. Previously, we
showed that wholebody bioimaging technology can be
used to follow replication of TK
+ recombinant WRvFire
and IHD-J-Luc vaccinia strains expressing luciferase
reporter gene in live mice [46,47]. Using this model sys-
tem, we explored how anti-MV and anti-EV polyclonal
sera limit VACV dissemination in mice. Our findings
demonstrate that cocktails comprised of a combination
of anti-EV polyclonal antibodies are more effective than
anti-MV antibodies in preventing virus replication and
dissemination from the nasal cavity to lungs, spleen and
liver. However, the most significant protection from
weight loss and pox lesion development was achieved by
a combination of anti-EV and anti-MV polyclonal anti-
bodies. This proof-of-concept study revealed that DNA
vaccine technology can indeed be used to make a cock-
tail of polyclonal antibodies that can be used as a viable
immunotherapeutic to treat Orthopoxvirus disease.
Results
Sera from NHP vaccinated with the 4pox DNA vaccine
protected mice against lethal respiratory challenge with
VACV
Previously, we demonstrated that it was possible to vac-
cinate NHP with the 4pox (L1, A27, B5, A33) DNA vac-
cine using various gene-based delivery technologies and
protect against lethal MPXV [32,34]and Golden, J.W., et
al manuscript in forthcoming). To test whether the
humoral responses produced by these vaccines were suf-
ficient to confer protection, we tested sera from NHP
vaccinated with either the 4pox DNA vaccine (L1, A33,
B5 and A33), L1R-alone or Dryvax, for the capacity to
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key sera (NMS) and murine monoclonal antibodies were
included as controls. Sera were injected subcutaneously
1 day before challenge withV A C V .T h e4 p o xa n dD r y -
vax sera protected all mice from lethal disease (Figure
1A). In contrast, sera from NHP vaccinated with the L1
DNA only protected 50% of the mice, and all of the ani-
mals receiving NMS sera or a negative control mouse
MAb succumbed to disease. Weight loss in mice
injected with the 4pox or Dryvax sera was similar to the
weight loss in mice receiving 100 μg of L1-specific posi-
tive controls MAb-7D11 or MAb-10F5, indicating simi-
lar mild disease in these groups (Figure 1B). These data
indicated for the first time that sera from a NHP vacci-
nated with a molecular smallpox vaccine can confer
protection in a model of orthopoxvirus disease.
Vaccination of rabbits with L1R, A27L, B5R and A33L DNA
vaccines by muscle electroporation elicits antibody
responses against each target immunogen
To investigate the possibility of producing a protective
immunogen-specific polyclonal antibody cocktail using
DNA vaccine technology, we used individual DNA vac-
cine plasmids to produce polyclonal antibodies in sepa-
rate rabbits. Rabbits were vaccinated three times by
muscle electroporation on days 0, 28, and 56 with DNA
vaccines encoding L1, A27, B5, or A33 proteins. Sera
collected on days 0, 28, 42, and 70 were evaluated for
anti-poxvirus antibodies by immunogen-specific ELISA,
PRNT, and EV inhibition assay (Figure 2). ELISA results
are shown in Figure 2A. All prevaccination (day 0) sera
were negative for VACV-specific antibodies by ELISA.
After a single vaccination, anti-L1, -A27, and -B5 anti-
bodies were detected, while antibodies against A33 were
not detected until after the second vaccination with the
A33R DNA vaccine. After the third vaccination (day
70), high-titer antibodies against L1 (GMT = 4.3), A27
(GMT = 3.9), B5 (GMT = 4.6), and A33 (GMT = 5)
were produced. PRNT results are shown in Figure 2B.
As expected [28,30-34], only the A27L and L1R DNA
vaccines elicited MV neutralizing antibodies. Two of the
three rabbits vaccinated with L1R developed neutralizing
antibodies after one vaccination, and all three developed
titers > 1000 after the third vaccination. Only two of the
three rabbits vaccinated with A27L developed neutraliz-
ing antibodies, both after the second vaccination. EV
inhibition assay results are shown in Figure 2C. Sera
from rabbits vaccinated with A33R, B5R, or A27L DNA
vaccines were tested for a capacity to inhibit the spread
of EV. EV spread was inhibited by sera from animals
vaccinated with either B5R or A33R DNA vaccines, but
not by the A27L vaccine (Figure 2C). The anti-B5
response was more effective than the anti-A33 responses
at inhibiting EV spread. We also examined the ability of
anti-EV antibodies to neutralize or disrupt EV particles
i nt h ep r e s e n c eo ra b s e n c eof complement + anti-L1
MAb-10F5. Sera from B5-vaccinated rabbits neutralized
EV particles in the presence or absence of complement
with titers of 180 and > 1280, respectively (Figure 2D).
In contrast, anti-A33 sera only neutralized EVs in the
presence of complement with a titer of > 1280. Sera
from A27-vaccinated animals did not neutralize EVs.
Together, these findings demonstrated that it was possi-
ble to use muscle electroporation for plasmid DNA vac-
cination to generate polyclonal antibodies that not only
bound to L1, A27, A33, and B5, but also were function-
ally active; two of the vaccines (L1R and A27L) elicited
MV neutralizing antibodies, and the other two vaccines
(A33 and B5) elicited antibodies that inhibited EV
spread in cell culture.
Bioimaging of normal BALB/c mice infected with IHD-J-
Luc recombinant vaccinia virus after prophylactic
treatments with immune rabbit sera
Having generated antibodies against L1, A27, B5 and
A33, we next characterized the ability of these molecules
to prevent viral dissemination and protect mice from
lethal VACV infection when delivered as combinations
against the EV and/or MV particles. Equal volumes of
day 70 sera from rabbits vaccinated with the L1R, A27L,
A33R, and B5R DNA vaccines were combined to make
a quadrivalent polyclonal antibody (QVPA) cocktail at a
1:1:1:1 ratio (Table 1). QVPA was characterized by
ELISA, PRNT, and an EV-spread assay to confirm bind-
ing and functional activity. ELISA titers (log10)a g a i n s t
L1, A33, A27, and B5 were 4, 4, 5, and 5, respectively.
The VACV PRNT50 titer was 3620. The QVPA reprodu-
cibly inhibited EV spread when diluted 1:100 (data not
shown). Additionally, QVPA neutralized EV particles
with an EV neutralization titer of 80. In the presence of
complement the EV neutralization titer markedly
increased to > 1280. Anti-MV (A27 and L1) and anti-
EV (A33 and B5) targeting combinations where gener-
ated such that the amount of antibodies against each
target were equimolar to that of the QVPA. Further-
more, to better understand the mechanisms by which
QVPA, anti-MV, and anti-EV rabbit sera protect ani-
mals, we used whole-body bioimaging to follow virus
replication and dissemination to the lungs and internal
organs after intranasal inoculation of BALB/c mice with
IHD-J-Luc recombinant VACV expressing luciferase
[46,47]. Mice were inoculated with a single dose of the
anti-MV, anti-EV, or QVPA cocktails, with NRS, or
with PBS in control 1 day before intranasal challenge
with 10
5 PFU of IHD-J-Luc and were followed for survi-
val and weight loss (Figure 3). Control mice and mice
that received NRS succumbed to death between days 7-
8. QVPA sera protected 100% of mice from lethality, as
Golden et al. Virology Journal 2011, 8:441
http://www.virologyj.com/content/8/1/441
Page 3 of 18well as morbidity as judged by significantly reduced
weight loss on days 5, 6, and 7 compared with control
animals (Figure 3A and 3B and Table 2). Anti-EV cock-
tail protected 100% of mice against IHD-J-Luc-induced
lethality, yet it did not protect from weight loss (Figure
3A and 3B and Table 2). Anti-MV cocktail did not pro-
tect from lethality or from weight loss in the IHD-J-Luc
challenge model (Figure 3).
All mice were subjected to bioimaging daily for 10
days using IVIS 50 instrument and bioluminescence
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Figure 1 Sera from vaccinated NHP can protect mice from lethal VACV challenge. Groups of eight mice were injected subcutaneously with
heat-inactivated sera collected from NHP previously vaccinated [34] with Dryvax (NHP ID# CH63 ref. x), 4pox DNA vaccine (NHP ID# CH93), L1R
DNA vaccine (NHP ID# CH63), or an irrelevant DNA vaccine (NHP ID# CH02). As positive controls for protection, groups of eight mice were
injected with 100 μg of purified anti-L1 murine monoclonal antibodies MAb-7D11 or MAb-10F5. As negative controls, eight mice received 100
μg of an irrelevant murine monoclonal antibody (MAb-3d7). One day after injection with NHP sera or murine MAbs, the mice were challenged
with 2 × 10
6 PFUPFU of VACV strain IHD-J intransally. Percent survival (A) and percent group weight loss (B) were plotted. In this experiment,
individual mouse weights were not recorded.
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Figure 2 Antibody responses after vaccination with individual poxvirus DNA vaccines administered using muscle electroporation.A .
Sera collected from three rabbits vaccinated with pWRG/A33R, or pWRG/B5R, or pWRG/A27L, or pWRG/TPA-L1R(opt) were tested for antibodies
that bind A33, B5, A27, and L1 by immunogen-specific ELISA. Symbols represent mean endpoint ELISA titers ± SE. The limit of detection was a
titer of 2 log10 (dashed line). B. Sera from rabbits vaccinated with the MV-specific targets, L1 and A27, were tested for VACV neutralizing
antibodies by PRNT. Titers for each time-point are shown for individual rabbits. The limit of detection was a titer of 20 (dashed line). C. Day 70
sera from rabbits vaccinated with the EV-specific targets, A33 and B5, were tested for their capacity to prevent the spread of EV in an EV spread
inhibition assay. Sera from rabbits vaccinated with pWRG/A27L were included as negative controls. Other controls included wells that were
overlain with methylcellulose after the adsorption step (no EV spread) and well that received media without dilute sera (no sera control).
Symbols represent sera diluted 1:14-1:56. Numbers of satellite plaques per well are shown as scatter graphs. The mean ± SD for each serum
sample is shown. Rabbit ID # and the plasmid vaccine used to generate the sera are shown on the x-axis. D. Sera from rabbits were diluted and
samples were incubated with fresh EV particles in the presence or absence of complement as indicated. EV neutraliation titers were determined
as described in the material and methods. The limit of detection was a titer of 40 (dashed line).
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used to calculate mean total fluxes ± SD (Figure 4A-D).
Representative images collected on sequential days from
control group and from QVPA-treated group exhibiting
bioluminescence in the nasal cavity, lungs, spleen, and
liver are shown in the Additional File 1. Background
bioluminescence in internal organs was measured in
BALB/c mice before infection and the mean total fluxes
were around 10
4 photons/second (p/s) in the nasal cav-
ity, liver, and spleen and 10
5 p / si nt h el u n g s( D a t an o t
shown). At 24 h postinfection with IHD-J-Luc, all mice
exhibited bioluminescence signal in the nasal cavity that
was on average two logs above background (Figure 4A).
In PBS-treated mice and in mice that received NRS or
anti-MV cocktail, mean total fluxes increased rapidly
within first 4 days postinfection and were maintained at
high levels until mice succumbed to death (Figure 4A,
Additional File 1A, and data not shown). In the nasal
cavities of QVPA and of anti-EV pretreated mice, viral
replication increased between days 2-6 and then
returned to background levels by day 10-14 (Figure 4A).
None of the immune rabbit sera prevented initial disse-
mination of IHD-J-Luc from the site of inoculation to
internal organs (lungs, liver, or spleen) (Figure 4B, C
and 4D). Yet clear differences between treatment groups
were noted. In mice that received QVPA and anti-EV
cocktails, the mean total fluxes within the internal
organs increased during days 1-4, reached plateau on
days 4-6, and then dropped to background levels on day
8 (Figure 4B-D blue and red lines). In contrast, mice
that received anti-MV cocktail showed higher signals
throughout the observation period and the curves were
indistinguishable from the NRS control group. Mean
total fluxes were 2 logs higher in mice from MV- and
from NRS-treated groups that survived by day 8 com-
pared with mice that received QVPA or anti-EV cocktail
(Figure 4B-D).
To determine if differences in total fluxes between
mice that received rabbit sera and control mice were
significant, we subjected total fluxes recorded in indivi-
dual mice between days 2 and 6 to t statistic (Figure 4E-
H). All values above the horizontal lines represent statis-
tically significant differences between total fluxes of a
given treatment group compared with PBS-treated con-
trol animals. The mean total fluxes in the nasal cavity
were significantly different between mice that received
anti-EV or QVPA cocktails and control mice on days 3-
6 or 4-6, respectively (Figure 4E red and blue bars). In
the lungs, anti-EV and QVPA significantly reduced
mean total fluxes on days 5 and 6 and on days 3, 5, and
6, respectively. In the liver, the significant differences for
the same groups were observed on days 2-6 (Figure 4G),
and in the spleen on days 3, 5, and 6 and days 3-6,
respectively (Figure 3F and 3H). NRS and anti-MV
cocktail did not significantly reduce mean total fluxes in
any organ (Figure 4E-H, green and purple bars).
Altogether these data showed that QVPA and anti-EV
cocktails, but not anti-MV cocktail, protected animals
from lethality and significantly reduced viral replication
at the site of inoculation, as well as in the lungs, spleen,
and liver. Importantly, the reduction in viral replications
was observed as early as day 3 in the nasal cavity, liver,
and spleen, and was sustained for the following days.
Thus, bioimaging allowed us to confirm that effective
protection from lethality by rabbit immune sera corre-
lated with early (day 3-4) reduction of viral loads in key
organs.
Reduction in pox formation after pretreatment with
antibody cocktails
We next examined the ability of immune rabbit sera to
prevent pox formation in the tails of infected mice. Pox
lesions were scored as bioluminescence foci on the tails
of each animal on days 3-6 postchallenge (Figure 5A).
All control animals, animals that received NRS, or anti-
MV cocktail generated pox lesions (Figure 5B and 5C).
QVPA cocktail both dramatically reduced the numbers
of mice with pox lesions and the number of pox lesions
per animal (Figure 5B and 5C). All mice that received
anti-EV cocktail developed pox lesions but the numbers
of lesions per animal were significantly lower than in
control group (Figure 5B and 5C). These data showed
that QVPA cocktail that contains antibodies against
both EV and MV viral isoforms was the most efficient
in preventing pox lesion development. The anti-EV anti-
body cocktail curtailed virus dissemination to internal
organs (Figure 4), but did not completely prevent pox
lesion formation. Anti-MV antibodies did not affect pox
lesions on their own, but did contribute to protection
from pox lesion development when combined with the
anti EV antibodies in the QVPA cocktail
QVPA protects SCID mice from lethal disease
Scarification of severely immunodeficient mice (SCID)
results in expanding lesions at the vaccination site in a
manner that closely resembles human progressive vacci-
nia, a severe life-threatening complication observed with
Table 1 Polyclonal antibody cocktails used in studies
Day 70 rabbit sera
Cocktail anti-L1R anti-A27 anti-A33 anti-B5 ratio
QVPA #2834 #2485 #2478 #2482 1:1:1:1
anti-MV #2834 #2485 - - 1:1
anti-EV - - #2478 #2482 1:1
NRS #1339 - - - NA
NRS = normal rabbit sera
NA = not applicable
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Figure 3 Testing of rabbit sera cocktails against MV, EV, or a combination of MV and EV (QVPA) in a lethal IHD-J-Luc vaccinia virus
intranasal challenge model. BALB/c mice were inoculated with anti-MV (purple), anti-EV (red), or QVPA (blue) cocktails, or with normal rabbit
sera, (NRS, green) one day before challenge with IHD-J-Luc; control mice received similar volumes of PBS and are shown in black. Mice were
observed for lethality (A) and for weight loss (B) for 21 and 14 days, respectively. The anti-MV cocktail contained1:1 mixture of anti-L1 and anti-
A27 sera. Anti-EV cocktail contained 1:1 mixture of anti-B5 and anti-A33 sera. QVPA (Lot 1) contains both anti-MV and anti-EV polyclonal sera and
PBS as described in Material and Methods. The IHD-J-Luc control group, n = 9, all other groups, n = 6.
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to test the protective efficacy of QVPA. Mice were trea-
ted with 0.2 mL of placebo (PBS), 10 mg of VIGIV, 0.2
mL of QVPA at 1:10 or 1:100 dilutions in PBS, or 0.2
mL of NRS at 1:10 in PBS on days 2, 5, 10, and 15. The
VIGIV used in this experiment had a PRNT50 titer =
453. ELISA titers (log10) against L1, A33, A27, and B5
were 2, 3.5, 3, and 4, respectively. We previously
demonstrated that this aggressive VIGIV therapeutic
regimen protects immunocompromised mice against
progressive vaccinia [49]. Here, survival in the VIGIV
treatment group was 85%, with 0% of placebo mice sur-
viving. QVPA was also effective in preventing death in
infected mice under identical treatment conditions,
although a dose response was not observed (Figure 6A).
As expected, VIGIV treatment resulted in lesion regres-
sion in all mice by day 19. QVPA at either 1:10 or 1:100
also resulted in lesion regression in most mice and cor-
related with survival (Figure 6B). Several mice receiving
NRS also resolved the primary lesion, although they suc-
cumbed to VACV infection in a manner similar to pla-
cebo treated mice.
Discussion
Polyclonal antibodies targeting both the Orthopoxvirus
MVs and EVs are critical for protection
VIGIV is known to contain antibodies that bind proteins
on both the MV and EV [22,50,51]. More importantly,
this polyclonal product contains antibodies that neutra-
lize both MV and EV. Although it is not clear which
antibody subset in VIGIV is involved in protective
immunity, it is likely both subsets contribute to protec-
t i o n .O u rg r o u pf o u n d[ 3 0 , 3 1 , 3 4 ] ,a n di tw a sl a t e ri n d e -
pendently confirmed [24], that combinations of antigens
targeting the two particles types of orthopoxviruses pro-
vided superior protection in vaccinated animals. Simi-
larly, Lutsig et al, demonstrated that monoclonal and
polyclonal antibody combinations targeting these mole-
cules provided enhanced protection compared to target-
ing individual viral molecules [52]. Here, we expanded
these studies and analyzed the impact of polyclonal anti-
bodies targeting EV and MV particles individually or
both EV/MV particles together (QVPA). Using
bioluminescent virus, we observed several differences in
the ability of anti-EV and anti-MV antibodies to protect
mice from VACV IHD-J. Anti-MV antibodies in
immune sera failed to provide protection against VACV
IHD-J, whereas antibodies against EV provided protec-
tion from lethality and significantly reduced viral repli-
cation at the site of inoculation (nasal cavity) and
reduced dissemination and/or replication in the lungs,
spleen, and liver. QVPA was most efficient in protecting
from lethality, and dissemination, and unlike anti-EV
cocktail, also significantly reduced weight loss. In addi-
tion, QVPA significantly reduced numbers of pox
lesions in surviving mice. Thus, of the three tested com-
binations, the EV and QVPA were similarly efficient in
preventing lethality, yet only QVPA also protected from
morbidity and pox lesion formation, suggesting that
both anti-EV and anti-MV antibodies are required for
complete protection.
The precise mechanism(s) by which anti-EV and anti-
MV antibodies mediated protection was beyond the
scope of this investigation. However, several mechan-
isms, none mutually exclusive, have been proposed.
Data from several studies indicate that anti-MV antibo-
dies mediate protection by neutralizing MV during
initial target cell interactions (e.g., attachment and pene-
tration) and by neutralizing MV released from lysed
infected cells or disrupted EV [53-58], and Schmaljohn
A., personal communication). Anti-EV antibody
mediated protection appears to be more complex and
likely involves multiple mechanisms [26,59,60]. These
may include the ability of anti-EV antibodies to prevent
viral egress [60], thereby preventing EV spread in vivo,
or to prevent EV binding and entry [26]. Recently, using
anti-B5 monoclonal antibodies, a role for complement
in protection was reported by the Crotty group [61].
Lustig et al, produced some evidence to suggest a syner-
gistic protective role of anti-EV and anti-MV antibodies
[ 5 8 ] .I nt h i sm o d e l ,a n t i - E Va n t i b o d i e sp l a yar o l ei n
complement-mediated disruption of the EVs, followed
by MV neutralization by anti-MV targeting antibodies.
This may explain why combinations of antibodies tar-
geting both particle types are more effective at protec-
tion compared to individually targeting each particle.
We showed that both anti-A33 and anti-B5 antibodies
are capable of disrupting EV particles in the presence of
complement (Figure 2D), making the resultant MVs
subject to neutralization by anti-MV antibodies. Inter-
estingly, contrary to anti-B5 sera, anti-A33 antibodies
did not neutralize EV in the absence of complement.
These findings suggest that anti-A33 protection is pre-
dominantly mediated by complement, whereas anti-B5
mediated protection can be complement dependent or
independent. In the experiments described in this
report, rabbit antibodies were used in a murine system.
Table 2 Mean weight change in mice challenged with
VACV IHD-J following administration of rabbit sera
Percent weight change
Treatment Day 5 Day 6 Day 7
PBS -14.8 ± 4.7 -20.0 ± 4.2 -26.8 ± 3.0
Anti-MV -12.4 ± 4.3 -17.8 ± 6.3 -24.8 ± 3.6
Anti-EV -16.0 ± 5.7 -19.3 ± 6.2 -22.2 ± 5.1
Anti-QVPA -7.4 ± 4.8* -7.7 ± 8.3* -10.3 ± 8.3**
NRS -15.4 ± 3.7 -19.5 ± 2.7 -23.3 ± 2.2
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Figure 4 Bioluminescence in the organs of mice pretreated with rabbit sera before infection with IHD-J-Luc. Mice were inoculated s. c.
with anti-MV (purple), anti-EV (red) cocktails, or with QVPA (blue), NRS (green), or PBS (black) on day -1 and were infected with IHD-J-Luc VACV
on day 0. Animals were subjected to whole-body imaging daily for 10 days. Bioluminescence in the nasal cavity (A, E), lungs (B, F), liver C, G),
and spleen (D, H) was recorded and used to calculate mean total fluxes ± SD (A-D) and t-statistic (E-H). Axis “y” in panels E-H shows the value
of t; t ≥ 2.16 is significant at a = 0.05 (two-tailed) for groups of 6 mice; t = 2.16 is depicted with broken horizontal line (E-H).
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Figure 5 Effect of anti-MV and anti-EV rabbit sera on pox development in mice challenged with IHD-J-Luc. IHD-J-Luc challenged mice
described in the legend to Figure 4 were subjected to whole-body imaging. The representative images of tails of three mice from the control
group (PBS treatment) recorded on day 3 (top panel) and day 5 (lower panel) are shown (A). Pox lesions were scored using sequential daily
images and used to calculate mean number of pox lesions per animal per day ± SD on days 3-6 (B, C) and total number of animals that
developed pox lesions during observation period (C).
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ment is suboptimal [62]. Thus, it is likely that comple-
ment did not play as much of a role in the observed
protection that it would in a homologous system.
Regardless of mechanism, our findings clearly demon-
strate that addition of both EV and MV targeting anti-
bodies resulted in superior protection.
Antibodies against each antigen contribute to protection
The polyclonal anti-MV antibodies alone did not confer
significant protection in the VACV IHD-J i.n. challenge.
However, as shown in Figure 1, it is possible to protect
mice in the intranasal VACV IHD-J challenge model
using high concentrations of anti-MV monoclonal anti-
bodies. In that experiment, anti-L1 monoclonal antibo-
dies, MAb-7d11 or MAb-10F5, at a 100 μg/mouse dose
were protective. Both anti-L1 MAbs used in the
experiment had a 50% neutralization titer of ~10 ng/ml.
This value is the same that was reported for MAb-7D11
by Wolfe et al. [54]. Thus, the 100 μg dose was equiva-
lent to 10,000 neutralizing units per mouse. A dose-ran-
ging study using MAb-10F5 in the VACV IHD-J
intranasal model demonstrated that the protective effect
was diminished to 80% when 5,000 neutralizing units/
mouse were delivered, and undetectable when 500 neu-
tralizing units were delivered (Figure 7). The anti-MV
titer in QVPA PRNT50 titer = 3620. Thus, the 0.3 ml
dose delivered had only 1086 neutralizing units per
mouse; a dose insufficient for significant protection in
the absence of anti-EV antibody.
The polyclonal anti-EV component alone conferred a
significant level of protection in the VACV IHD-J
mouse model. The anti-A33 and anti-B5 antibodies
within this cocktail were capable of preventing the
Figure 6 Efficacy of immune rabbit sera in a mouse model of progressive vaccinia. Groups of 6-week old SCID/NCr mice (n = 7/group)
were scarified with VACV, then treated i.p. with PBS (placebo), VIGIV (10 mg), QVPA (1:10; 1:100), or NRS (1:10) on days 2, 5, 10, and 15. (A)
Survival was monitored out to 60 days postinfection. VIGIV and both QVPA dose groups showed a statistically significant increase (p < 0.05) in
median survival time compared to placebo or NRS. (B) Primary lesion size on day 19 was determined from digital photographs and compared
using one way ANOVA and Tukey’s multiple comparison. Treatment with VIGIV or either dose of QVPA resulted in statistically significant
reduction (p < 0.01) in lesion area.
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antibodies were conferring protection by binding EV
and inhibiting spread in vivo. Our data demonstrate that
there was less spread within the nasal cavity, less spread
to the liver, lungs, and spleen, and even less spread as
measured by tail pox lesions. It is possible that the anti-
EV antibodies within the cocktail are also involved in
destruction of infected cells or other means of infection
clearance. The more rapid clearance of virus from the
nasal cavity, lungs, liver, and spleen (Figure 4) when
anti-EV antibodies were present support this possibility;
however, at this time we do not have any direct evi-
dence that antibodies in the QVPA are involved in anti-
body-dependent cell-mediated cytotoxicity (ADCC) or
complement-dependent cytotoxicity (CDC).
An alternative to VIGIV
VIGIV is an integral component of a multilayer strategy
to defend against orthopoxviruses, in particular as it
relates to biodefense preparedness. In recent years it has
been used in combination with other experimental
drugs to treat serious adverse events associated with
vaccination with the smallpox vaccine. For example, in
2009 VIGIV was used to treat a military smallpox vacci-
nee with progressive vaccinia [48]. In addition to its
value in treating vaccine adverse reactions, it is also
likely that VIG would be considered for use as an emer-
gency prophylactic or therapeutic during an Orthopox-
virus o u t b r e a k ,s u c ha st h eN o r t hA m e r i c a nM P X V
outbreak in 2003 [63]. Despite its importance, the
precise anti-vaccinia antibody composition of VIGIV
and the mode of action of this drug are poorly under-
stood. As is the case with all plasma-derived products,
despite donor screening, plasma testing, and viral inacti-
vation steps used during manufacture, there remains the
risk of transmission of blood-borne viral or prion dis-
ease. Immune globulin intravenous (human) products
have also been associated with various adverse events
such as renal dysfunction, hypersensitivity reactions, and
thrombotic events [64]. Moreover, the amount of VIGIV
needed to treat adverse events might be underestimated,
as is its interaction with other co-administered thera-
peutics. In the 2009 progressive vaccinia case, a total of
16,740,000 units of intravenous VIGIV were adminis-
tered during over 3 months, along with oral and topical
ST-246, CMX001, and topical imiquimod. The total
amount of product administered was more than 334
doses, an amount previously thought sufficient for up to
30 patients [48]. These factors have led health officials
to suggest replacing VIGIV with a new product with
high-specific activity, well defined antibody specificity
and a similar or improved safety profile [12,13]. Poten-
tial VIGIV-replacements include human monoclonal
antibodies [47,65], humanized monoclonal antibodies
[66], and chimpanzee anti-B5 and anti-A33 monoclonal
antibodies [67,68].
The 4pox DNA vaccine targets immunogens located
on the MV (L1 and A27) and EV (A33 and B5). This
vaccine establishes protective immunity against ortho-
poxviruses as evidenced in several Orthopoxvirus
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Figure 7 Titration of protection conferred by passive transfer of anti-L1 monoclonal antibody in VACV IHD-J mouse model. Groups of
seven (50 μg dose) to 10 (5 and 0.5 μg groups) mice were inoculated s. c. with purified anti-L1 MAb-10F5 diluted in PBS. The next day, all 27
mice were challenged with 2 × 10
6 PFUPFU of virus intransally. Mice were monitored for 20 days. Moribund animals, or animals that lost more
than 30% of their starting weight, were euthanized. Days 0-14 are shown. No additional animals succumbed after day 12.
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[32,34] and Golden, J.W. et al manuscript forthcoming).
The current study demonstrates that the antibodies pro-
duced by this vaccine are sufficient for protection, even
in immunocompromised mice (Figure 6). Despite being
a crude serum preparation, QVPA provided significant
protection against progressive vaccinia in the mouse
model. The level of protection was comparable to that
provided by a total dose of 40 mg of VIGIV, which is a
purified IgG preparation, suggesting that a combination
of specific MV and EV components may result in a
treatment with high specific activity. There could be
some non-specific inhibitory effects associated with the
introduction of heterologous (rabbit) sera into mice
because several animals treated with NRS had reduced
lesion size compared to placebo but, nevertheless, still
demonstrated a similar median survival time compared
to placebo controls. The ability of our 4pox DNA vac-
cine platform to generate highly potent protective poly-
clonal antibodies against defined and protective
Orthopoxvirus targets argues this system could be a sui-
table replacement for VIGIV that was produced from
pooled plasma from Dryvax-vaccinated individuals.
QVPA offers an advantage over monoclonal mixtures,
another possible VIGIV replacement, because monoclo-
nal antibody escape mutants have been shown to exist
among poxviruses. For example, a single-point mutation
in L1 at amino acid position 35 can prevent viral neu-
tralization by some otherwise neutralizing antibodies
[53]. This is a result of changes in the tertiary structure
of the previously reported L1 neutralizing epitope [69].
Accordingly, polyclonal antibodies may be preferable for
new immunoglobulin product seeking to mitigate the
deleterious events associated with a bioterrorism event
involving Orthopoxvirus, in particular genetically modi-
fied viruses. Additionally, redundant targeting of the EV
particles will be critical. We have reported that antibo-
dies against A33 do not efficiently cross-interact with
orthologs from VACV and MPXV [27]. Furthermore,
others have reported similar cross-reactively problems
associated with VACV and VARV B5 [70]. Therefore,
any future immunotherapeutic should target both mole-
cules, as well as the MV to ensure adequate cross-
protection.
Genetic vaccines for immunotherapeutic production
There is an emerging concern that some hostile entities
may deploy biological weapons (BW) as weapons of
mass destruction [71-73]. This concern is augmented by
official United States Government reports expressing
fear that BW technology is much cheaper and easier to
obtain compared to nuclear, and yet can deliver signifi-
cant destruction [74]. From a broader standpoint, the
use of DNA vaccination technology as a platform for
establishing protective immunity against bioterrorism
threat agents is particularly alluring because it has the
potential for rapid development of scalable vaccines
(months versus years) that are human-safe. This rapid
development is facilitated by the fact that molecular vac-
cines consist of DNA, which is obtainable by the advent
of sophisticated genomic sequencing, even without the
need to isolate an organism (e.g., sequencing the patho-
gen genome from infected tissue and de novo synthesis
of desired target, such as glycoproteins) [75]. DNA can
be produced under good-manufacturing product specifi-
cations (GMP) without the need for complex and time-
consuming processes of growing/attenuating/killing
virus or protein purification [76,77]. The data presented
in this study suggest another benefit of this technology
could be the relatively rapid generation of protective
antibodies. These antibodies could be used to aid in
protection against threat agents whose release into the
environment is imminent or occurring. These antibodies
could also be utilized in diagnostic tests. Moreover, the
antibodies could be used as immunotherapeutics to
bridge the immunity of persons exposed to threats while
vaccine-induced immunity builds. It could also enhance
and speed up adaptive immune responses through the
rapid generation of immune complexes in vivo [78].
This is similar to postexposure treatment of rabies,
where anti-rabies antibodies are co-administrated with
the vaccine [79]. DNA vaccine technology would seem
particularly useful for protection strategies involving the
simultaneous use of antibodies and vaccine, as the effi-
cacy of gene-based vaccines are not reduced by neutra-
lizing antibodies whereas the efficacy of whole virus
containing vaccine can be impacted by the presence of
antibodies. The notion of using DNA vaccines to
develop human-safe immunotherapeutics is augmented
by the development of humanized recombinant animal
systems that possess the ability to generate human anti-
bodies, including cattle capable of generating nearly-
human antibodies [80] and by direct cloning of human
heavy and light Ig chains from antigen-specific B cells
after smallpox vaccination (55). Such antibodies would
circumvent potential reactogenicity of antibodies made
in other species. The extent by which DNA vaccine
technology can be used to develop immunotherapeutics
against infectious agents, including biological threat
agents for which neither immune sera produced using
licensed vaccines nor convalescent sera/plasma are avail-
able, is a matter for future exploration.
Materials and methods
Animals
Female BALB/c and SCID/NCr mice were obtained
from the National Cancer Institute and used for passive
transfer experiments. Female New Zealand white rabbits
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vaccination. All animal work was approved by institu-
tional animal care and use committees.
Cells and viruses
VACV Connaught vaccine strain (derived from the New
York City Board of Health strain), VACV strain WR
(ATCC VR-1354), and VACV strain IHD-J (obtained
from Dr. Alan Schmaljohn) were all maintained in
VERO cell (ATCC CRL-1587) monolayers grown in
Eagle minimal essential medium, containing 5% heat-
inactivated fetal bovine serum (FBS), 1% antibiotics (100
U/ml penicillin, 100 μg/ml of streptomycin, and 50 μg/
ml of gentamicin), 10 mM HEPEs (cEMEM). A HeLa
cell passage of the smallpox vaccine virus (Dryvax;
derived from the New York City Board of Health strain
and produced as a vaccine by Wyeth) was obtained
from the laboratory of Dr. Michael Merchlinsky via
Hana Golding (CBER, FDA). COS-7 (COS) cells (ATCC
CRL-1651) were used for transient expression experi-
ments. BSC-1 cells (ATCC CCL-26) were used for pla-
que-reduction neutralization assays (PRNT) and EV
spread assays. Both BSC-1 and COS-7 cells were also
maintained in cEMEM.
DNA vaccination of rabbits by electroporation
Rabbits were vaccinated using muscle electroporation as
described previously [81]. Briefly, acclimated female
New Zealand white rabbits were vaccinated with 1.3 mg
of plasmid DNA per vaccination per animal using an
Inovio (San Diego, CA) Twin Injector electroporation
device. Rabbits were vaccinated on days 0, 28, 56, and
sera for QVPA were collected on day 70.
Immunogen-specific ELISA
VACV histidine-tagged antigens L1 (300 ng/well), A33
(50 ng/well), B5 (50 ng/well) and A27 (50 ng/well), pro-
duced in Escherichia coli or mammalian cells (B5 anti-
gen produced in baby hamster kidney cells) and purified
on nickel columns, were diluted in 0.1 M carbonate buf-
fer [pH 9.6] and plated in duplicate in the wells of a
high-binding, 96-well plate (Corning; Corning, NY). The
ELISA was performed in an identical manner as pre-
viously described (40). For assays involving anti-pox
mouse antibodies, the secondary antibody was hydrogen
peroxidase conjugated goat anti-mouse Ig (Sigma Cat
no. A4416) diluted 1:1000; and for assays involving anti-
pox rabbit antibodies, the secondary antibody was
hydrogen peroxidase conjugated goat anti-rabbit Ig
(KPL Cat no. 04-15-06) diluted 1:1000. For assays invol-
ving VIGIV, the secondary antibody was hydrogen per-
oxidase conjugated goat anti-human IgG, A, M (KPL
Cat no. 074-1007) diluted 1:500. End-point-titers were
determined as the highest dilution with an absorbance
value greater than the mean absorbance value from at
least three normal sera plus three standard deviations.
Neutralization Titers
The plaque-reduction neutralization test (PRNT) invol-
ving VACV strain IHD-J and BSC-1 cells was described
previously (43). All sera tested in the PRNT were incu-
bated at 56°C for 30 min. Plaques were counted and the
percent neutralization was calculated relative to the
number of plaques in the absence of antibody. Titers
represent the reciprocal of the highest dilution resulting
in a 50% reduction in the number of plaques. Mean
neutralization titers for individual mice were plotted ±
standard deviation.
Anti-EV functional antibody assays
The EV spread inhibition assay was performed as fol-
lows. VACV strain IHD-J was diluted in cEMEM to give
~25 PFU/ml. Aliquots of this viral suspension (100 μl)
were adsorbed onto BSC-1 confluent cell monolayer in
6-well plates for 1 h in a 37°C 5% CO2 incubator. Plates
were rocked ~15 min. After adsorption cells were rinsed
once with cEMEM and sera from the indicated groups
was added to the wells. All serum samples were heat
activated at 56°C for 30 min prior to use. After 18 h in
a 2 ml semisolid overlay (Earle’s basal minimal essential
medium, 1.5% methyl cellulose, 5% heat-inactivated FBS,
supplemented with antibiotics (100 U/ml penicillin, 100
μg/ml of streptomycin, and 50 μg/ml of gentamicin))
was added to each well. The cells were incubated for 3
da t3 7 ° Ci na5 %C O 2 incubator. On day 3, cell mono-
layers were stained with 1 ml of a staining solution (3%
crystal violet and 15% ethanol in H2O). Satellite plaques
were counted and the percent spread inhibition was cal-
culated relative to the number of plaques in the absence
of antibody. All samples were analyzed in duplicate.
The EV neutralization assay was preformed as
reported previously [66]. Briefly, fresh EV particles (75-
100 PFU) were incubated for 1 h with the indicate sera
(diluted twofold starting at a 1:40) in the presence or
absence of 5% baby rabbit complement (Cedarlane) in
200 μL total volume. After incubation, 180 μlo ft h e
mixture was adsorbed for 1 h on BSC-1 cell monolayers
in 6-well plates. Warm PBS was used to wash away
unbound virus and 2 ml semisolid overlay (see above)
was added to each well. All samples included an anti-
MV antibodies, MAb-10F5 (1:100) which targets the L1
molecule [30]. After 4 days, plaques were stained with
crystal violet as described above. Plaques were counted
and the percent neutralization was calculated relative to
the number of plaques in the absence of anti-EV anti-
body or in the absence of anti-EV antibody, but in the
presence of complement. EV neutralization titers repre-
sent the reciprocal of the highest dilution resulting in a
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zation titers for individual mice were plotted ± standard
deviation.
Passive transfer of antibodies
For experiments using non-luciferase expressing VACV,
Groups of eight BALB/c mice (9-11-weeks old) were
anesthetized, ear tagged, weighed, and bled on day -7.
On day -1 the mice were weighed again and then 300
μL of the indicated heat-inactivated rabbit or NHP
serum from a previous study [34] were injected subcuta-
neously behind the neck. For combinations of rabbit
sera, 75 μL of each PAb were administered in a total
volume 300 μL. For monoclonal antibodies, the indi-
cated concentration of MAb was diluted in PBS in a
total volume of 300 μL and injected subcutaneously
behind the neck.
VACV strain IHD-J challenges
For experiments using non-luciferase expressing
V A C V ,m i c ew e r ea n e s t h e t i z e da n dw e i g h e db e f o r e
intranasal administration of 50 μl of PBS containing 2
×1 0
6 PFU of VACV strain IHD-J using a plastic pip-
ette tip (25 μl per nare). This dose is three times the
LD50. Subsequently, mice were observed and weighed
daily for 14 d. Moribund mice (> 30% body weight)
were euthanized.
Progressive vaccinia model
Aliquots of HeLa-passaged Dryvax (VACV, New York
Board of Health strain) were removed from -70°C sto-
rage, thawed on ice, and sonicated for three cycles each
consisting of 15 sec at 90% power, 50% duty cycle and
15 sec on ice. Virus was diluted to the required concen-
tration in cDMEM (Dubelco’s minimal essential medium
containing 10% fetal bovine serum, 4.5 mg/mL of D-glu-
cose, 110 μg/mL of sodium pyruvate, 100 μM nonessen-
tial amino acids, 100 U/mL of penicillin/streptomycin,
and 0.25 μg/mL of amphotericin) and kept on ice before
scarification. To perform scarification, mice (n = 7 per
group) were anesthetized with ketamine/xylazine and
the fur removed from the lower back area using clip-
pers. Ten μl of the virus inoculum (i.e., 10
6 PFU/mL for
a1 0
4 PFU challenge) were pipetted onto the skin cover-
ing the cartilageous area proximal to the base of the tail.
A bifurcated vaccination needle (Precision Medical Pro-
ducts, Denver, PA) was used to deliver 20 punctures
through the inoculums solution. VIGIV (10 mg), QVPA
(1:10 or 1:100 in PBS), or normal rabbit sera (NRS)
(1:10 in PBS) was administered via intraperitoneal (i.p.)
injection on days 2, 5, 10, and 15 after VACV exposure.
Mice were monitored for clinical signs including weight
loss, ruffled fur, breathing difficulties, or hunched pos-
ture. Mice that lost 25% of their original body weight,
exhibited limping or guarding behavior of a limb,
remained hunched after stimulation, had difficulty
breathing, had severe swelling of the mouth or throat
interfering with eating or drinking, or were moribund
were euthanized according to preset euthanasia criteria.
Method for measuring lesion size
Lesion area analysis was performed with ImageJ using
digital photographs and a calibrated reference as
described in Rasband, W.S., ImageJ, U. S. National Insti-
tutes of Health, Bethesda, Maryland, USA, http://imagej.
nih.gov/ij/, 1997-2011.
Whole-body bioimaging using luciferase expressing VACV
A recombinant IHD-J vaccinia virus expressing lucifer-
ase (IHD-J-Luc) was constructed by Dr. Jerry Weir and
Michael Merchlinsky and kindly provided for this study
(81). Five-week-old female BALB/c mice (National Can-
cer Institute, Frederick, MD) were used in bioimaging
experiments. Mice were anesthetized before infection by
i.p. injection of 20 μl per g of body weight of 2, 2, 2-tri-
bromoethanol dissolved in tertiary amyl alcohol and
diluted in sterile PBS according to manufacturer’s
instructions. Mice were challenged i.n. with 10
5 PFU (2
LD50) of IHD-J-Luc in 10 μl volume delivered in one
nostril.
Animals received a single dose administration of PBS,
NRS, anti-EV, anti-MV, or QVPA cocktails in 400 μl
volumes delivered via s. c. injections at the upper part
o ft h eb a c k1d a yb e f o r ec h a l l e n g e .T h ea n t i - E Va n d
anti-MV cocktails were diluted 1:1 with PBS before
injection to maintain similar concentration of anti-EV
and anti-MV antibodies as in QVPA, The handling of
mice and experimental procedures used in bioimaging
were approved by the CBER animal study review
committee
In vivo measurements of luciferase activity
Ten to 15 min before imaging, mice received a single
injection of D-luciferin potassium salt (Caliper Life
Sciences, Hopkinton, MA) at 150 μg/g body weight, i. p.
After anesthesia in the oxygen-rich induction chamber
with 2% isofluorane, mice were imaged using IVIS 50
cooled charge-coupled device camera system (Caliper)
as previously described [46]. Images were collected daily
during first 10 days postchallenge, and were analyzed
with the LivingImage 3.02 software (Caliper). The
amount of light emitted by replicating virus in live ani-
mals was measured by establishing a single region of
interest (ROI) for each organ as recommended by the
manufacturer. The background bioluminescence was
determined using images of D-luciferin-injected animals
1 day before infections and was subtracted from experi-
mental values.
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Kaplan Meier survival curves of time-to-death after
infection were generated using standard GraphPad
Prism V5 software. Total lesion areas on day 19 were
compared using one-way ANOVA and Tukey’s multiple
comparison test. t-statistic was employed to compare
mean total fluxes between infected control mice (PBS-
treated) and infected and treated mice (anti-EV, anti-
MV, QVPA, and NRS) using Microsoft Excel.
Additional material
Additional file 1: Images of mice infected with IHD-J-Luc and either
treated or not with anti-QVPA cocktail. Mice described in the legend
to Figure 4 were subjected to whole-body imaging daily for 10 days or
during survival. Representative sequential images of mice 1, 2, and 3
from control group (PBS only, panels A and C) and of mice 1, 2, and 3
from the group that received QVPA (panels B and D) are shown. Images
of heads (A, B) were acquired from the same mice as images of the
torso (C, D) but using shorter exposure to avoid saturation of the camera
due to high signal from the nasal cavity. Images from control and from
treated mice were collected on day 1-6 (A, C) and on day 1-9 (B, D),
respectively.
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